Literature DB >> 1384791

Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages.

F Birg1, M Courcoul, O Rosnet, F Bardin, M J Pébusque, S Marchetto, A Tabilio, P Mannoni, D Birnbaum.   

Abstract

FLT3, a receptor belonging to the FMS/KIT family and localized to 13q12, could play a role in the biology of early hematopoietic progenitor cells. Because FMS and KIT are expressed in both normal progenitors and myeloid leukemias, we looked for FLT3 expression in fresh human leukemic cells using Northern blot analysis. High levels of FLT3 expression were detected in 92% of the cases of acute myeloid leukemia (AML) tested, ranging from the M1 to the M5 stages of differentiation assessed in the French-American-British classification. Immature (MO) AML cells, biphenotypic leukemias, and AML with megakaryocytic differentiation (M7 subtype) also expressed the FLT3 transcript. FLT3 was also expressed at high levels in acute lymphoid leukemias of T and B origins. Finally, it was not expressed in chronic myeloid leukemias in chronic phase, whereas it was expressed in most blast crisis samples. This pattern of expression of FLT3 contrasts with the expression of FMS and KIT restricted to myeloid leukemias, and suggests that the FLT3 product could play a role in the expansion of the leukemic blasts of both the myeloid and lymphoid lineages.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384791

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.

Authors:  Kathleen M Murphy; Mark Levis; Michael J Hafez; Tanya Geiger; Lisa C Cooper; B Douglas Smith; Donald Small; Karin D Berg
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

2.  Functional domains of the ubiquitous chromatin protein DEK.

Authors:  Ferdinand Kappes; Ingo Scholten; Nicole Richter; Claudia Gruss; Tanja Waldmann
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

3.  RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.

Authors:  Ayuna Hattori; Daniel McSkimming; Natarajan Kannan; Takahiro Ito
Journal:  Leuk Res       Date:  2017-01-11       Impact factor: 3.156

4.  Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.

Authors:  Obdulio Piloto; Melissa Wright; Patrick Brown; Kyu-Tae Kim; Mark Levis; Donald Small
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

5.  Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Authors:  Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

6.  Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.

Authors:  Manabu Kurokawa; Takahiro Ito; Chih-Sheng Yang; Chen Zhao; Andrew N Macintyre; David A Rizzieri; Jeffrey C Rathmell; Michael W Deininger; Tannishtha Reya; Sally Kornbluth
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-16       Impact factor: 11.205

Review 7.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

8.  High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia.

Authors:  Hyoung Jin Kang; Ji Won Lee; Sang Hyeok Kho; Min Jeong Kim; Young Jin Seo; Hyery Kim; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

Review 9.  FLT3 inhibitors for the treatment of autoimmune disease.

Authors:  Katharine A Whartenby; Donald Small; Peter A Calabresi
Journal:  Expert Opin Investig Drugs       Date:  2008-11       Impact factor: 6.206

10.  Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis.

Authors:  Mamdooh Gari; Adel Abuzenadah; Adeel Chaudhary; Mohammed Al-Qahtani; Huda Banni; Waseem Ahmad; Fatin Al-Sayes; Sahira Lary; Ghazi Damanhouri
Journal:  Int J Mol Sci       Date:  2008-11-11       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.